We are live on ! Find out more
ROSG

Rosetta Genomics Ltd.
ROSG

Delisted

ROSG was delisted on the 21st of May, 2018.

Back to rankings

11 hedge funds and large institutions have $689K invested in Rosetta Genomics Ltd. in 2016 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

22% more funds holding

Funds holding: 9 → 11 (+2)

12% less capital invested

Capital invested by funds: $780K → $689K (-$91K)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

Holders
11
Holders Change
+2
Holders Change %
+22.22%
% of All Funds
0.27%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
2
Reduced
3
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$377K
2
Morgan Stanley
Morgan Stanley
New York
+$74.2K
3
Citadel Advisors
Citadel Advisors
Florida
+$27.1K
4
VKH
Virtu KCG Holdings
New York
+$25K
5
SEI Investments
SEI Investments
Pennsylvania
+$2.07K

Top Sellers

Rank Fund Capital Flow
1
HCM
Highlander Capital Management
New Jersey
-$52.7K
2
UBS Group
UBS Group
Switzerland
-$4.67K
3
TSS
Two Sigma Securities
New York
-$1.76K

ROSG Hedge Fund Activity: Q4 2016 in Review

11 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Rosetta Genomics Ltd. (ROSG) for Q4 2016, worth a combined $689K — down 12% from $780K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new ROSG positions and 1 closed out — a net gain of 2 holders — while 2 added to existing stakes and 3 trimmed.

The largest buyer was Sabby Management, opening a new position worth an estimated $377K. The largest seller was Highlander Capital Management, cutting an estimated $52.7K.

  • 11 institutional investors held Rosetta Genomics Ltd. (ROSG) as of Q4 2016, up from 9 in Q3 2016.
  • Funds reported $689K of Rosetta Genomics Ltd. stock for Q4 2016, down 12% quarter-over-quarter.
  • 3 funds opened new Rosetta Genomics Ltd. positions in Q4 2016 and 1 closed out, a net change of +2 holders.
  • The largest Rosetta Genomics Ltd. buyer in Q4 2016 was Sabby Management, an estimated $377K added.
  • The largest Rosetta Genomics Ltd. seller in Q4 2016 was Highlander Capital Management, an estimated $52.7K sold.

Based on aggregated 13F filings for Q4 2016.